What's New in Age-Related Macular Degeneration Treatment? FDA-Approved Drugs to Know

Treatment for age-related macular degeneration has changed significantly in the United States, especially as newer FDA-approved medicines have entered routine eye care. For many patients, the biggest shift is that doctors now have more ways to slow disease activity, reduce retinal swelling, and in some cases extend the time between office visits. At the same time, these therapies work differently depending on whether a person has wet AMD or dry AMD, and they do not all offer the same balance of convenience, risk, or expense.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

New FDA-Approved AMD Treatments

For wet AMD, anti-VEGF drugs remain the mainstay of treatment. These medicines help block signals that cause abnormal blood vessels to grow and leak under the retina. Newer approved options include Vabysmo, which targets both VEGF-A and Ang-2, and Susvimo, a refillable eye implant that continuously delivers ranibizumab. For advanced dry AMD with geographic atrophy, FDA-approved drugs now include Syfovre and Izervay. These two medications do not reverse vision loss, but they are designed to slow the enlargement of retinal damage over time, which is a major development in a field that previously had no approved drug treatment for this stage of dry AMD.

Dry vs. Wet AMD Treatments

Dry vs. wet AMD is one of the most important distinctions in treatment planning. Wet AMD is usually treated with injections or implanted delivery systems because the immediate goal is to control leakage, bleeding, and rapid vision changes. Commonly used drugs include Eylea, Lucentis, Vabysmo, Beovu, and the Susvimo implant system. Dry AMD, by contrast, often progresses more slowly, and early or intermediate dry AMD is usually managed with monitoring, lifestyle measures, and in some patients AREDS2-based supplements rather than prescription injections. When dry AMD advances to geographic atrophy, newer drugs such as Syfovre and Izervay may be considered to slow progression, but they still require regular treatment and careful follow-up.

Comparing Newer AMD Drugs

Comparing newer AMD drugs means looking beyond the drug name alone. Benefits can include longer intervals between injections, a different mechanism of action, or access to treatment for conditions that once had no approved drug option. Risks also differ. Anti-VEGF injections for wet AMD can cause eye irritation, increased eye pressure, inflammation, or, rarely, infection. Geographic atrophy treatments have raised discussion about the rate of lesion growth slowing, treatment frequency, and possible side effects such as inflammation or conversion to wet AMD in some patients. In practice, the right choice often depends on disease type, imaging results, response to prior therapy, and how often a patient can realistically return for care.

Costs and real-world pricing

Cost is a major part of what patients should know. In real-world settings, prices may vary based on insurance coverage, Medicare rules, supplemental plans, treatment setting, and whether the amount discussed is a list price, an allowed amount, or an out-of-pocket cost. Injection frequency also matters: a medicine with a higher per-dose price may not always lead to higher yearly spending if it can be given less often for some patients. The comparison below uses publicly discussed U.S. list-price or benchmark estimates for branded products and should be treated as a general guide rather than a guaranteed bill.

Prices, rates, or cost estimates mentioned in this article are based on the latest available information but may change over time. Independent research is advised before making financial decisions.

Monitoring, risks, and long-term outlook

Even with newer therapies, treatment success depends on regular monitoring with retinal imaging and vision checks. Some patients respond quickly, while others need medication changes or different dosing intervals. Doctors also watch for side effects such as intraocular inflammation, infection after injections, rising eye pressure, or signs that dry AMD has converted to wet AMD. Long-term outlook has improved because approved treatments can slow damage more effectively than in the past, but expectations still need to stay realistic. Most current therapies are designed to preserve vision for as long as possible, not to fully restore retinal tissue that has already been lost.

The newest FDA-approved AMD treatments have expanded what eye specialists can offer, especially for wet AMD and for geographic atrophy linked to dry AMD. The main differences between these drugs involve disease type, dosing schedule, side-effect profile, and cost rather than a single universal winner. For patients in the United States, the most useful way to understand treatment options is to separate dry from wet AMD first, then compare how each approved medicine fits the pattern of vision changes, follow-up needs, and long-term disease control.